|
Neoplasms
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Neoplasms
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Neoplasms
|
|
0.710 |
GeneticVariation
|
BEFREE |
Next-generation sequencing identified recurrent mutations in HRAS (Q61R) in 3 of 5 IUPs, described for the first time in this neoplasm.
|
25097040 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mutations in RAS genes (HRAS G13R, KRAS G12D, KRAS Q61R, NRAS Q61R) were detected in benign lesions and HRAS Q61R, NRAS Q61K mutations in PTCs.
|
31085772 |
2019 |
|
Solid/Multicystic Ameloblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among the BRAF wild-type cases, 1 UAM showed a missense SMO mutation (p.L412F), whereas 2 NRAS (p.Q61R), 2 HRAS (p.Q61R), and 2 FGFR2 (p.C383R) activating mutations were identified in AM.
|
30216733 |
2019 |
|
Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
RNA sequencing and Sanger sequencing identified PIK3CA (p.E545K/p.H1047R) and/or HRAS (p.Q61R) hotspot mutations in 6 of 8 (75%) apocrine carcinomas.
|
29443014 |
2018 |
|
Eccrine porocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hotspot HRAS mutations were identified in two poromas (p.G13R and p.Q61R) and one porocarcinoma (p.G13C).
|
29269125 |
2018 |
|
melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The rarity of HRAS and KRAS Q61R mutants in malignant melanoma</span> let previous investigations erroneously conclude that SP174 is specific for NRAS Q61R-mutant protein.
|
29206715 |
2018 |
|
Recurrent tumor
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, we identified a co-occurring somatic HRAS (p.Q61R) activating point mutation and MEN1 frameshift mutation (p.L117fs) present in a primary and recurrent tumor from one patient.
|
27175596 |
2016 |
|
Medullary carcinoma of thyroid
|
|
0.010 |
GeneticVariation
|
BEFREE |
Of the seven RET wild-type MTCs, four cases (57.1 %) harbored a RAS mutation: three in HRAS (all Q61R) and one in KRAS (G12R).
|
24828033 |
2014 |
|
Familial medullary thyroid carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Of the seven RET wild-type MTCs, four cases (57.1 %) harbored a RAS mutation: three in HRAS (all Q61R) and one in KRAS (G12R).
|
24828033 |
2014 |
|
Inverted urothelial papilloma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Next-generation sequencing identified recurrent mutations in HRAS (Q61R) in 3 of 5 IUPs, described for the first time in this neoplasm.
|
25097040 |
2014 |
|
Follicular Variant Thyroid Gland Papillary Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Overall, 13 cases (46%) harbored RAS mutations, including seven (25%) with NRAS mutations (p.Gln61Arg) and six (21%) with HRAS mutations (five had p.Gln61Arg and one had a p.Gln61Lys substitution).No PE/WC FVPTCs had BRAF mutations.
|
23477374 |
2013 |